Andrew Cho, Ph.D., is a Senior Advisor in Oligonucleotide Analytics at Eli Lilly and Company, contributing to the Lilly Institute for Genetic Medicine since September 2025. Prior to this, Andrew held positions at Intellia Therapeutics, Inc., and Magenta Therapeutics, where responsibilities included the acquisition and implementation of advanced mass spectrometry techniques for RNA characterization and analytical development. Andrew's earlier experience includes roles in clinical analytical chemistry at Sonic Reference Laboratory and a technician internship at Trinity Pharmacy. Academically, Andrew earned a Bachelor of Science in Chemistry from The University of Texas at Austin and a Ph.D. in Analytical Chemistry from Texas Tech University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices